Emergent BioSolutions | EBS - Créanciers Commerciaux





Créanciers Commerciaux Changement Date
Acadia Pharmaceuticals USD 44.57M 32.32M 2026-06
Akebia Therapeutics USD 9.42M 1.04M 2026-06
ALKERMES USD 142.86M 40.5M 2026-06
Alnylam Pharmaceuticals USD 108.02M 18.61M 2026-06
Amarin USD 18.8M 29.36M 2026-06
ANI Pharmaceuticals USD 73.83M 4.14M 2026-06
BioMarin Pharmaceutical USD 913.67M 120.52M 2026-06
Coherus Biosciences USD 13.17M 1.69M 2026-06
Emergent BioSolutions USD 112.2M 500K 2023-12
Exelixis USD 39.06M 14.91M 2026-06
Glaxosmithkline GBP 14.34B 6.39B 2026-03
Heron Therapeutics USD 11.64M 2.67M 2026-06
Ionis Pharmaceuticals USD 47.7M 21.67M 2026-06
Ironwood Pharmaceuticals USD 3.24M 339K 2026-03
Lexicon Pharmaceuticals USD 3M 87K 2026-03
Lonza CHF 471M 3M 2024-12
Merck USD 3.83B 36M 2026-06
Moderna USD 167M 6M 2026-06
Myriad Genetics USD 30.4M 2.2M 2026-06
Nektar Therapeutics USD 10.03M 744K 2026-03
Neurocrine Biosciences USD 691.3M 145.8M 2026-03
Pacira USD 17.51M 3.5M 2026-06
Pfizer USD 4.58B 75M 2026-06
PTC Therapeutics USD 40.45M 14.96M 2026-06
Sanofi EUR 23.6B 888M 2026-06
Sarepta Therapeutics USD 50.98M 19.39M 2026-06
United Therapeutics USD 497.8M 500K 2026-06
Vanda Pharmaceuticals USD 39.09M 33.28M 2024-12